ChartAid
An on-device clinical AI assistant for outpatient doctors that drafts visit notes, surfaces relevant guidelines and reconciles medication lists — all running locally so protected health information never leaves the tablet.
Outpatient physicians and small group practices worried about cloud AI vendors
- Local scribe that turns the visit conversation into a SOAP note
- Offline medication interaction checker over a bundled Rx database
- Patient-friendly after-visit summaries generated on-device in plain German or English
- Compliance mode that locks the app when the device is not on a trusted Wi-Fi
Hospital CIOs are starting to reject cloud AI scribes over BAA and cross-border data risks; an on-device alternative unlocks the rest of the market.
Healthcare AI spending hit $1.4B in 2025 (nearly 3x 2024), and ambient AI scribe adoption among ambulatory providers is rising rapidly (e.g., 58–90% surgeon adoption in one pilot); outpatient documentation burden is a clear and growing pain point.2025: The State of AI in Healthcare | Menlo Ventures ↗Ambient AI-assisted clinical documentation in surgical outpatient care ↗
The ambient AI scribe market is extremely crowded with Microsoft DAX Copilot, Abridge, Nabla, DeepScribe, Suki, Freed, and Notable Health all targeting the same physicians; the on-device sub-niche is barely served (only open-source tools like OpenMed exist), leaving limited but real whitespace.Ambient AI Scribe Comparison Guide 2026: DAX, Abridge, Nabla, and DeepScribe ↗OpenMed · On-Device Clinical AI for NER and PHI De-Identification ↗
Practices already pay $49–$700/provider/month for AI scribes (human scribes cost $32K–$42K/yr); on-device privacy positioning could justify a premium but limits enterprise stickiness and reduces recurring cloud-cost lock-in.AI Medical Scribe Pricing: What Practices Actually Pay in 2026 ↗AI Medical Scribes 2025: Complete Guide, Pricing & Reviews ↗
BAA/HIPAA gaps with cloud AI scribes are a documented and growing concern (multiple 2024–2026 analyses flag ongoing oversight, cross-border data, and verification issues cloud BAA alone doesn't solve); regulatory pressure on PHI is a durable tailwind for on-device.The HIPAA Problem Your AI Vendor's BAA Doesn't Solve ↗AI Medical Scribe HIPAA Risks: What Your Vendor Isn't Telling You ↗
Local LLMs like Phi-3, Llama 3.2, and Gemma 3 now run on phones/tablets via MLX/Ollama, and open-source clinical NER/PHI tools (OpenMed) exist as building blocks; however, producing draft-quality visit notes, guideline retrieval, and medication reconciliation simultaneously on a tablet with clinical-grade accuracy remains hard — large specialized models strain mobile memory and latency.On-Device AI in 2026: Running LLMs Locally on Your Phone, Laptop, and Tablet ↗OpenMed · On-Device Clinical AI for NER and PHI De-Identification ↗